Successful treatment with rituximab in a patient with stiff-person syndrome complicated by dysthyroid ophthalmopathy

Internal Medicine

Volumn 49, Issue 3, 2010, Pages 237-241

  Katoh, Nagaaki ^a   Matsuda, Masayuki ^a   Ishii, Wataru ^a   Morita, Hiroshi ^a   Ikeda, Shu Ichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti glutamic acid decarboxylase (GAD) antibody; Dysthyroid ophthalmopathy; Rituximab; Stiff person syndrome

Indexed keywords

ALPRAZOLAM; BACLOFEN; CD20 ANTIGEN; COTRIMOXAZOLE; DIAZEPAM; GADOLINIUM; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; IMMUNOGLOBULIN; INSULIN; LEVOTHYROXINE; LIOTHYRONINE; RITUXIMAB; THIAMAZOLE; THYROGLOBULIN ANTIBODY; THYROID ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE;

ABDOMEN; ADULT; ANTIBODY BLOOD LEVEL; ANXIETY; ARTICLE; BACK; CASE REPORT; CLINICAL EFFECTIVENESS; DIPLOPIA; ELECTROMYOGRAPHY; EMOTIONAL STRESS; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; EXTRAOCULAR MUSCLE; FEMALE; FOLLOW UP; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GAIT DISORDER; GOITER; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMAGE ENHANCEMENT; INSULIN DEPENDENT DIABETES MELLITUS; LEG; LEG MUSCLE; MONOTHERAPY; MOTOR UNIT POTENTIAL; MUSCLE HYPERTROPHY; MUSCLE RIGIDITY; MUSCLE SPASM; MUSCLE STIFFNESS; MUSCLE STRENGTH; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOPLEGIA; PHYSICAL EXAMINATION; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; STIFF MAN SYNDROME; THERAPY EFFECT; THYROID FUNCTION;

ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; BIOLOGICAL FACTORS; DIABETES MELLITUS, TYPE 1; FEMALE; GLUTAMATE DECARBOXYLASE; GRAVES OPHTHALMOPATHY; HUMANS; MIDDLE AGED; STIFF-PERSON SYNDROME;

EID: 77749245795     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.2821     Document Type: Article

References (20)

1. Espay AJ, Chen R. Rigidity and spasms from autoimmune encephalomyelopathies: stiff-person syndrome. Muscle Nerve 34: 677-690, 2006.
2. Levy LM, Dalakas MC, Floeter MK. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of γ-aminobutyric acid. Ann Intern Med 131: 522-530, 1999.
3. Levy LM, Levy-Reis I, Fujii M, Dalakas MC. Brain γ-aminobutyric acid changes in stiff-person syndrome. Arch Neurol 62: 970-974, 2005.
4. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 345: 1870-1876, 2001.
5. Mourits MP, Prummel MF, Wiersinga WM, Koorneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol 47: 9-14, 1997.
6. De Camilli P, Thomas A, Cofiell R, et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of stiff-man syndrome with breast cancer. J Exp Med 178: 2219-2223, 1993.
7. Butler MH, Hayashi A, Ohkoshi N, et al. Autoimmunity to gephyrin in Stiff-Man syndrome. Neuron 26: 307-312, 2000.
8. McCabe DJ, Turner NC, Chao D, et al. Paraneoplastic "stiff person syndrome" with metastatic adenocarcinoma and anti-Ri antibodies. Neurology 62: 1402-1404, 2004.
9. Baker MR, Das M, Isaacs J, Fawcett PR, Bates D. Treatment of stiff person syndrome with rituximab. J Neurol Neurosurg Psychiatry 76: 999-1001, 2005.
10. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12: 177-186, 1997.
11. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445, 1994.
12. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 6: 859-866, 2006.
13. Salvi M, Vannucchi G, Campi I, et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156: 33-40, 2007.
14. Bonara P, Vannucchi G, Campi I, et al. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy. Clin Rev Allergy Immunol 34: 118-123, 2008.
15. Salvi M, Vannucchi G, Campi I, Curro N, Beck-Peccoz P. New immunomodulators in the treatment of Graves' ophthalmopathy. Ann Endocrinol (Paris) 69: 153-156, 2008.
16. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833, 1998.
17. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 48: 1484-1492, 2003.
18. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev 8: 144-146, 2008.
19. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113: 4834-4840, 2009.
20. Klöppel G, Löhr M, Habich K, Oberholzer M, Heitz PU. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 4: 110-125, 1985.